<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342819</url>
  </required_header>
  <id_info>
    <org_study_id>CREC-SA.0054/10/2019</org_study_id>
    <nct_id>NCT04342819</nct_id>
  </id_info>
  <brief_title>The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.</brief_title>
  <acronym>EFFECT</acronym>
  <official_title>The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of The West Indies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of The West Indies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mechanistic effects of empagliflozin on platelet function profiles have not yet been
      ascertained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sodium GLucose Transport 2 inhibitors (SGLT2I), including empagliflozin, reduce the
      likelihood of hospitalization for heart failure and death in persons with type 2 diabetes, of
      which the mechanism has not been fully elucidated. The mechanistic effects of empagliflozin
      on platelet function profiles have not yet been ascertained. It remains unclear if this
      reduction in cardiovascular death is mediated by decreased platelet reactivity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study will be of a prospective, single-arm, crossover trial design over a 2-year period. Patients at the Eric Williams Medical Sciences Complex (EWMSC), Mt. Hope, Trinidad and Tobago.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reaction Units</measure>
    <time_frame>14 days</time_frame>
    <description>Platelet Reaction Units post-Empagliflozin</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Platelet Dysfunction Due to Drugs</condition>
  <arm_group>
    <arm_group_label>SGLT2i</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin 25 mg per oral once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitor</intervention_name>
    <description>Sodium-Glucose Like Transporter 2 Inhibitor</description>
    <arm_group_label>SGLT2i</arm_group_label>
    <other_name>Empagliflozin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. between 18 and 74 years of age,

          2. have stable coronary artery disease and diabetes mellitus, already on DAPT with
             aspirin and clopidogrel for at least 6 months,

        Exclusion Criteria:

          1. presence of active internal bleeding or history of bleeding diathesis or clinical
             findings associated with an increased risk of bleeding,

          2. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial
             neoplasm, arteriovenous malformation, or aneurysm,

          3. history of clinical and/or hemodynamic instability,

          4. within 1 month of placement of a bare metal stent,

          5. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,

          6. planned coronary revascularization,

          7. treatment with fibrin-specific fibrinolytic therapy &lt;24 h or non-fibrin-specific
             fibrinolytic therapy &lt;48 h,

          8. use of an oral anticoagulation agent or international normalized ratio &gt;1.5,

          9. body weight &lt;60 kg,

         10. age &gt;75 years,

         11. hemoglobin &lt;10 g/dL,

         12. platelet count &lt;100×106/μL,

         13. creatinine &gt;2 mg/dL,

         14. hepatic enzymes &gt;2.5 times the upper limit of normal,

         15. pregnancy and/or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Naveen A Seecheran, MBBS, MSc</last_name>
    <phone>1-868-663-4332</phone>
    <email>naveen.seecheran@sta.uwi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanley L Giddings, MBBS</last_name>
    <phone>1-868-663-4332</phone>
    <email>stanley.giddings@sta.uwi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eric Williams Medical Sciences Complex</name>
      <address>
        <city>Port Of Spain</city>
        <state>North</state>
        <zip>00000</zip>
        <country>Trinidad and Tobago</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen A Seecheran, MBBS MSc</last_name>
      <phone>868-753-7686</phone>
      <email>naveen.seecheran@sta.uwi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sateesh Sakhamuri, MBBS DM</last_name>
      <phone>868-741-7184</phone>
      <email>sateesh.sakhamuri@sta.uwi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Trinidad and Tobago</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of The West Indies</investigator_affiliation>
    <investigator_full_name>Naveen Seecheran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

